治疗性HSV-2疫苗减少复发性病毒排放和复发性生殖器疱疹疾病
生殖器HSV-2感染者随机接受三个剂量队列的GEN-003疫苗(含gD2和ICP4蛋白及Matrix-M2佐剂)或安慰剂,肌内注射三剂,随访12个月。60µg抗原/50µg M2剂量组病毒排放率比为0.58,病变率、复发率和复发持续时间也降低;两种剂量均诱导抗体和细胞免疫应答并持续至12个月,安全性可接受。
要点
- GEN-003 60µg抗原/50µg M2组病毒排放率比为0.58,安慰剂组为1.06。
- 病变率、复发率和复发持续时间在接种后也降低。
- 75µg M2剂量组反应原性高于50µg M2组,尤其是疼痛、压痛、不适和疲劳。
核心结论
- GEN-003疫苗具有可接受的安全性,并刺激体液和细胞免疫应答。
- 60µg抗原/50µg M2剂量对病毒学和临床指标效果最大,值得进一步开发。
研究设计与样本
- HSV-2血清阳性且有生殖器疱疹者随机分为三个剂量队列:60µg抗原/50µg M2、60µg抗原/75µg M2或安慰剂。
- 肌内注射三剂,间隔21天;参与者每日两次采集生殖器区域拭子检测HSV-2并监测生殖器病变12个月。
- 比较接种前病毒排放率和病变率与接种后三个定义期间:第43-71天、第6个月和第12个月。
主要发现
- 60µg抗原/50µg M2组接种后立即减少HSV排放,率比为0.58;60µg/75µg M2组为0.75;安慰剂组为1.06。
- 病变率、复发率和复发持续时间也降低。
- 75µg M2剂量组反应原性高于50µg M2组,尤其是疼痛、压痛、不适和疲劳。
- 两种剂量均刺激抗体和细胞免疫应答,并持续至12个月。
关键数值与推荐
- 60µg抗原/50µg M2组病毒排放率比为0.58;60µg抗原/75µg M2组为0.75;安慰剂组为1.06。
临床怎么用
- GEN-003 60µg抗原/50µg M2剂量在减少病毒排放和临床指标方面效果最大,但需进一步开发验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genital herpes simplex virus (HSV) type 2 is a common persistent infection that frequently reactivates to cause recurrent lesions and recurrent viral shedding which is incompletely controlled by antiviral therapy. GEN-003 is a candidate therapeutic vaccine containing 2 HSV-2 proteins, gD2 and ICP4, and Matrix-M2 adjuvant (M2). METHODS: HSV-2 seropositive persons with genital herpes were randomized into three dose cohorts of Gen-003 (60 µg antigen/50 µg M2, 60 µg/75 µg M2 or Placebo). Three intramuscular doses 21 days apart of GEN-003 or placebo were administered. Participants obtained genital area swabs twice-daily for HSV-2 detection and monitored genital lesions for 12 months. The rates of virus shedding and lesion rates before vaccination were compared to 3 defined periods after vaccination; Days 43-71, Month 6 and Month 12. RESULTS: GEN-003 at a dose of 60 µg each antigen/50 µg M2 reduced HSV shedding immediately after dosing with a rate ratio of 0.58, compared to 0.75 for the GEN-003 60 µg/75 µg M2 and 1.06 for placebo. Lesion rates, recurrence rates, and duration of recurrences were also reduced. Reactogenicity was higher with the 75 µg M2 dose than the 50 µg M2 dose, specifically for pain, tenderness, malaise and fatigue. Antibody and cellular immune responses were stimulated by both doses and persisted to 12 months. CONCLUSIONS: GEN-003 vaccine manufactured with a scalable process gave results similar to those observed in prior clinical trials. GEN-003 had an acceptable safety profile and stimulated both humoral and cellular immune responses. The 60 µg antigen/50 µg M2 provided the maximal effect on virologic and clinical measures and warrants further development. (Funded by Genocea; ClinicalTrials.gov number NCT02515175).
引用
- Bernstein DI, Flechtner JB, McNeil LK, et al. Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease. Vaccine. 2019. PMID: 31103365. doi:10.1016/j.vaccine.2019.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。